Extrait

Tafenoquine (TQ) is an 8-aminoquinoline (8-AQ) drug for the radical cure of Plasmodium vivax malaria , and in Phase III development. It is envisaged that TQ may challenge primaquine (PQ), another 8-AQ, which is the current standard of care. Recently, several publications have indicated that CYP2D6 activity plays a role in PQ efficacy and have suggested that it may also extend to TQ efficacy (Pybus et al, 2013; Bennett et al, 2013, Marcsisin et al 2014). To deternmine the relationship between CYP2D6 enzymatic activity and TQ efficacy, a pharmacogenetic (PGx) analysis was conducted for subjects involved in TAF112582 (Part 1), a double-blind, placebo-controlled dosing ranging study

Critère d'inclusion

• Malaria, Vivax

Liens

• gsk